Shandong Sinobioway Biomedicine Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jialin Yue

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump

Oct 08

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price

Aug 19

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues

Mar 06

CEO

Jialin Yue (56 yo)

2.3yrs

Tenure

CN¥766,500

Compensatie

Mr. Jialin Yue is GM & Director of Shandong Sinobioway Biomedicine Co., Ltd. since August 5, 2022 and August 22, 2022 respectively and was its Co-GM since April 10, 2022 until August 22, 2022.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jialin Yue	GM & Director	2.3yrs	CN¥766.50k	geen gegevens
Wenjun Liu	Deputy GM & Non-Independent Director	2.3yrs	CN¥538.80k	geen gegevens
Hui Zhao	Board Secretary & Employee Director	2.6yrs	CN¥792.90k	geen gegevens
Ren Yanshen	Co-Founder	no data	geen gegevens	geen gegevens
Chen Zhangliang	Co-Founder	no data	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002581 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jialin Yue	GM & Director	2.3yrs	CN¥766.50k	geen gegevens
Wenjun Liu	Deputy GM & Non-Independent Director	2.3yrs	CN¥538.80k	geen gegevens
Hui Zhao	Board Secretary & Employee Director	2.3yrs	CN¥792.90k	geen gegevens
Xiuyuan Yu	Vice Chairman	8.9yrs	CN¥995.40k	geen gegevens
Xue Ming Yan	Member of the Supervisory Board	8.9yrs	geen gegevens	geen gegevens
Wenjie Yu	Director	2.3yrs	CN¥727.60k	geen gegevens
Guiyuan Huang	Non-Independent Director	2.3yrs	CN¥212.50k	geen gegevens
Zhe Zheng	Non-Independent Director	2.3yrs	CN¥33.30k	geen gegevens
Yang Liu	Independent Director	2.3yrs	geen gegevens	geen gegevens
Jie Xiao	Independent Director	2.3yrs	CN¥33.30k	geen gegevens
Yang Xia	Independent Director	2.3yrs	CN¥33.30k	geen gegevens
Jianuo Zeng	Non-Employee Supervisor	2.3yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002581 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Shandong Sinobioway Biomedicine Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, May 22, 2024

Shandong Sinobioway Biomedicine Co., Ltd. Announces Executive Appointments

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, Aug 22, 2022

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.067 (vs CN¥0.13 in 3Q 2023)

There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.003 loss per share (vs CN¥0.049 loss in 2Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price

Shandong Sinobioway Biomedicine Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

First quarter 2024 earnings released: CN¥0.042 loss per share (vs CN¥0.033 loss in 1Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, May 22, 2024

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues

Shandong Sinobioway Biomedicine Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.061 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.049 loss per share (vs CN¥0.033 profit in 2Q 2022)

Full year 2022 earnings released: CN¥0.022 loss per share (vs CN¥0.41 profit in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.061 (vs CN¥0.32 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.17 in 2Q 2021)

Shandong Sinobioway Biomedicine Co., Ltd. Announces Executive Appointments

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, Aug 22, 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.037 in 1Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.021 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.045 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.29 loss per share (vs CN¥0.096 profit in FY 2019)

New 90-day low: CN¥9.90

New 90-day low: CN¥12.64

New 90-day low: CN¥15.21

New 90-day low: CN¥17.15

Third quarter earnings released

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Beijing Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan

New 90-day low: CN¥17.55

First half earnings released

New 90-day low - CN¥19.50

Shandong Sinobioway Biomedicine Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd